Welcome to our dedicated page for OSR Holdings SEC filings (Ticker: OSRHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for OSR Holdings, Inc., focusing on the redeemable warrants trading under the symbol OSRHW on The Nasdaq Stock Market LLC, as well as related disclosures about the company’s common stock (OSRH). Through these filings, users can review how OSR Holdings, Inc. describes its healthcare activities, including oral immunotherapies, design-augmented biologics, and neurovascular intervention medical device and systems distribution in Korea.
Key filing types for OSR Holdings, Inc. include current reports on Form 8-K, which can describe material events such as annual meetings of stockholders, the election of directors, and stockholder votes on executive compensation, equity plans, and Nasdaq 20% issuance proposals. These documents help explain governance decisions and capital-related actions that may affect both the common stock and the OSRHW warrants.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, typically contain detailed descriptions of the company’s business, risk factors, and financial condition. For OSR Holdings, Inc., these filings can provide additional context on its healthcare focus and sector classification, as well as further information about its securities registered on Nasdaq.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections and explain complex disclosures in more accessible language. Users can quickly identify key points in lengthy documents, such as governance outcomes reported in Form 8-K, while still having direct access to the full text of each filing as it appears in the SEC’s EDGAR system.
joint protein central, inc. filed a Schedule 13G reporting beneficial ownership of 2,603,759 shares of OSR Holdings, Inc. common stock, representing 7.9% of the class. The filing shows sole voting power over 2,603,759 shares and no dispositive power. The form is signed by Senyon Choe, Director on 04/22/2026.
joint protein central, inc. filed a Schedule 13G reporting beneficial ownership of 2,603,759 shares of OSR Holdings, Inc. common stock, representing 7.9% of the class. The filing shows sole voting power over 2,603,759 shares and no dispositive power. The form is signed by Senyon Choe, Director on 04/22/2026.
OSR Holdings, Inc. appointed Yeiseok Kim as Chief Operating Officer, effective April 16, 2026. The Board approved his appointment on March 26, 2026, and an amended employment agreement provides for increased annual compensation.
Kim, age 36, previously served as a Senior Analyst at OSR Holdings Co., Ltd. from 2020 to 2025, supporting cross-border healthcare investments and pharmaceutical licensing. He holds a BA in Environmental Science from Seoul National University and an MS in Medicine from Jeonbuk National University, along with a Korean medical license obtained in 2019.
The company notes there are no special arrangements or understandings behind his appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
OSR Holdings, Inc. appointed Yeiseok Kim as Chief Operating Officer, effective April 16, 2026. The Board approved his appointment on March 26, 2026, and an amended employment agreement provides for increased annual compensation.
Kim, age 36, previously served as a Senior Analyst at OSR Holdings Co., Ltd. from 2020 to 2025, supporting cross-border healthcare investments and pharmaceutical licensing. He holds a BA in Environmental Science from Seoul National University and an MS in Medicine from Jeonbuk National University, along with a Korean medical license obtained in 2019.
The company notes there are no special arrangements or understandings behind his appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
OSR Holdings, Inc. executive Kim Yeiseok, the Chief Operating Officer, filed an initial Form 3 reporting beneficial ownership of 24,699 shares of the company’s Common Stock. These shares are reported as held directly, and the filing does not show any recent purchase or sale transactions.
OSR Holdings, Inc. executive Kim Yeiseok, the Chief Operating Officer, filed an initial Form 3 reporting beneficial ownership of 24,699 shares of the company’s Common Stock. These shares are reported as held directly, and the filing does not show any recent purchase or sale transactions.
OSR Holdings, Inc. entered into a second amendment to its equity line with White Lion GBM Innovation Fund, adding new intraday and fixed purchase mechanisms that let the company sell stock at 90% of the volume-weighted average price over defined trading periods, with threshold-price protections for certain purchases.
The company also agreed to issue a senior secured convertible promissory note with a principal amount of $1,055,555.55 to White Lion. OSR Holdings received $500,000 in cash and reduced approximately $2,019,290 of amounts outstanding under an existing warrant, effectively cancelling that warrant.
The note bears 5% annual interest, matures in nine months, and is initially convertible at the holder’s option at a $1.00 per share fixed price, with certain market-based conversion alternatives. Conversion generally cannot begin until six months after issuance and is limited by a 4.99% beneficial ownership cap, which White Lion may increase to 9.99%. The note is a senior secured obligation, backed by substantially all company assets, and was issued in a private placement relying on Securities Act exemptions.
OSR Holdings, Inc. entered into a second amendment to its equity line with White Lion GBM Innovation Fund, adding new intraday and fixed purchase mechanisms that let the company sell stock at 90% of the volume-weighted average price over defined trading periods, with threshold-price protections for certain purchases.
The company also agreed to issue a senior secured convertible promissory note with a principal amount of $1,055,555.55 to White Lion. OSR Holdings received $500,000 in cash and reduced approximately $2,019,290 of amounts outstanding under an existing warrant, effectively cancelling that warrant.
The note bears 5% annual interest, matures in nine months, and is initially convertible at the holder’s option at a $1.00 per share fixed price, with certain market-based conversion alternatives. Conversion generally cannot begin until six months after issuance and is limited by a 4.99% beneficial ownership cap, which White Lion may increase to 9.99%. The note is a senior secured obligation, backed by substantially all company assets, and was issued in a private placement relying on Securities Act exemptions.
OSR Holdings, Inc. filed an amended current report to correct an exhibit attached to a prior disclosure. The amendment replaces Exhibit 10.1 with a corrected version of the Global License Agreement for VXM01, dated March 23, 2026, among Vaximm AG, OSR Holdings, Inc. and BCM Europe AG. The update is described as fixing clerical errors, including the stated per share price, and does not change any other information contained in the original report.
OSR Holdings, Inc. filed an amended current report to correct an exhibit attached to a prior disclosure. The amendment replaces Exhibit 10.1 with a corrected version of the Global License Agreement for VXM01, dated March 23, 2026, among Vaximm AG, OSR Holdings, Inc. and BCM Europe AG. The update is described as fixing clerical errors, including the stated per share price, and does not change any other information contained in the original report.
OSR Holdings, Inc. entered into a binding term sheet with BCM Europe AG for a revised global exclusive license of VXM01, with OSR Holdings added as a direct counterparty and primary recipient of economics.
Upon a definitive license agreement, Vaximm AG will grant BCME an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. BCME will be responsible for up to $815.0 million in milestone payments payable directly to OSR Holdings, while OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million. Closing of a definitive agreement is subject to due diligence, board approvals, and an independent fairness opinion.
OSR Holdings, Inc. entered into a binding term sheet with BCM Europe AG for a revised global exclusive license of VXM01, with OSR Holdings added as a direct counterparty and primary recipient of economics.
Upon a definitive license agreement, Vaximm AG will grant BCME an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. BCME will be responsible for up to $815.0 million in milestone payments payable directly to OSR Holdings, while OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million. Closing of a definitive agreement is subject to due diligence, board approvals, and an independent fairness opinion.
OSR Holdings, Inc., formerly Bellevue Life Sciences Acquisition Corp., is now a global healthcare holding company following its February 14, 2025 business combination with Korea-based OSR Holdings Co., Ltd. The company focuses on acquiring and developing innovative pharma and medical device businesses.
Its three wholly owned subsidiaries are: Vaximm, which develops oral T‑cell immunotherapies including VXM01 for glioblastoma and pancreatic cancer with orphan drug designations; Darnatein, which designs biologics for bone and cartilage regeneration; and RMC, a Korean neurovascular device distributor being transformed into a healthcare 4PL logistics platform.
As of December 31, 2025, non‑affiliate equity value was about $7.7 million based on a $0.56 share price, and there were 33,124,755 common shares outstanding as of March 20, 2026. The filing highlights extensive patent portfolios and early- to mid‑stage clinical data but also significant development, financing and market risks.
OSR Holdings, Inc., formerly Bellevue Life Sciences Acquisition Corp., is now a global healthcare holding company following its February 14, 2025 business combination with Korea-based OSR Holdings Co., Ltd. The company focuses on acquiring and developing innovative pharma and medical device businesses.
Its three wholly owned subsidiaries are: Vaximm, which develops oral T‑cell immunotherapies including VXM01 for glioblastoma and pancreatic cancer with orphan drug designations; Darnatein, which designs biologics for bone and cartilage regeneration; and RMC, a Korean neurovascular device distributor being transformed into a healthcare 4PL logistics platform.
As of December 31, 2025, non‑affiliate equity value was about $7.7 million based on a $0.56 share price, and there were 33,124,755 common shares outstanding as of March 20, 2026. The filing highlights extensive patent portfolios and early- to mid‑stage clinical data but also significant development, financing and market risks.
OSR Holdings, Inc. furnished an update to ensure fair disclosure after inadvertently sharing non‑public information with a sell‑side analyst about its drug development subsidiary, Vaximm AG, and SillaJen, Inc.
Vaximm is in active, but non‑binding, negotiations with SillaJen over a potential licensing arrangement for Pexa‑Vec, an oncolytic immunotherapy in a Phase 2 FDA‑regulated study for renal cell carcinoma. Separately, OSR Holdings’ management has held very early, exploratory verbal discussions about potentially acquiring a controlling interest in SillaJen representing approximately 16% of its outstanding common shares. No term sheet, structure, financing, or definitive agreements exist for either the licensing or equity transaction, and the company stresses there is no assurance any deal will be completed. OSR Holdings indicates it does not plan further updates unless later developments independently require disclosure.
OSR Holdings, Inc. furnished an update to ensure fair disclosure after inadvertently sharing non‑public information with a sell‑side analyst about its drug development subsidiary, Vaximm AG, and SillaJen, Inc.
Vaximm is in active, but non‑binding, negotiations with SillaJen over a potential licensing arrangement for Pexa‑Vec, an oncolytic immunotherapy in a Phase 2 FDA‑regulated study for renal cell carcinoma. Separately, OSR Holdings’ management has held very early, exploratory verbal discussions about potentially acquiring a controlling interest in SillaJen representing approximately 16% of its outstanding common shares. No term sheet, structure, financing, or definitive agreements exist for either the licensing or equity transaction, and the company stresses there is no assurance any deal will be completed. OSR Holdings indicates it does not plan further updates unless later developments independently require disclosure.
OSR Holdings, Inc. received notice from Nasdaq that it has been granted an additional 180-day period, until August 31, 2026, to regain compliance with the Nasdaq minimum bid price rule requiring a bid of at least $1.00 per share.
The company was first notified on September 5, 2025, that its stock had traded below $1.00 for 30 consecutive business days and initially had until March 4, 2026, to regain compliance. Nasdaq granted more time because OSR Holdings meets all other Nasdaq Capital Market listing standards, including market value of publicly held shares.
If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days during this new period, Nasdaq will confirm that the company has regained compliance. OSR Holdings plans to monitor its share price and consider available options to meet Nasdaq’s bid price requirement.
OSR Holdings, Inc. received notice from Nasdaq that it has been granted an additional 180-day period, until August 31, 2026, to regain compliance with the Nasdaq minimum bid price rule requiring a bid of at least $1.00 per share.
The company was first notified on September 5, 2025, that its stock had traded below $1.00 for 30 consecutive business days and initially had until March 4, 2026, to regain compliance. Nasdaq granted more time because OSR Holdings meets all other Nasdaq Capital Market listing standards, including market value of publicly held shares.
If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days during this new period, Nasdaq will confirm that the company has regained compliance. OSR Holdings plans to monitor its share price and consider available options to meet Nasdaq’s bid price requirement.
OSR Holdings, Inc. completed the acquisition of South Korea-based medical device company Woori IO Co., Ltd. (WORIO) on January 26, 2026 through a share exchange under the Korean Commercial Act. OSR Holdings’ subsidiary OSR Holdings Co., Ltd. (OSRK) acquired all issued and outstanding WORIO shares, making WORIO a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.
Each WORIO share was exchanged for 0.948832 OSRK shares, and OSRK issued an aggregate of 84,338 new shares in exchange for 88,891 WORIO shares. The transaction was completed using equity in the subsidiary, and no OSR Holdings common stock was issued. OSR Holdings plans to file any required financial statements for this acquisition by amendment within 71 days.
OSR Holdings, Inc. completed the acquisition of South Korea-based medical device company Woori IO Co., Ltd. (WORIO) on January 26, 2026 through a share exchange under the Korean Commercial Act. OSR Holdings’ subsidiary OSR Holdings Co., Ltd. (OSRK) acquired all issued and outstanding WORIO shares, making WORIO a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.
Each WORIO share was exchanged for 0.948832 OSRK shares, and OSRK issued an aggregate of 84,338 new shares in exchange for 88,891 WORIO shares. The transaction was completed using equity in the subsidiary, and no OSR Holdings common stock was issued. OSR Holdings plans to file any required financial statements for this acquisition by amendment within 71 days.